RESUMEN
Saksenaea vasiformis is an emerging human pathogen, belonging to the order Mucorales of the subphylum Mucormycotina, most often associated with rhino-cerebral, cutaneous and subcutaneous infections following trauma. A review of the published literature was attempted on the occasion of a cutaneous leg infection with favorable outcome in a young immunocompetent man after mild injury. The overall aim was the facilitation of the study and the integrated understanding of this kind of fungal infections.
Asunto(s)
Inmunocompetencia , Traumatismos de la Pierna/complicaciones , Mucormicosis/diagnóstico , Adulto , Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Desbridamiento , Humanos , Inflamación , Pierna/microbiología , Pierna/patología , Traumatismos de la Pierna/microbiología , Imagen por Resonancia Magnética , Masculino , Mucorales/aislamiento & purificación , Mucorales/patogenicidad , Mucormicosis/tratamiento farmacológico , Mucormicosis/inmunologíaRESUMEN
We aimed to describe the current state of specialist obesity services for adults with clinically severe obesity in public hospitals in Australia, and to analyse the gap in resources based on expert consensus. We conducted two surveys to collect information about current and required specialist obesity services and resources using open-ended questionnaires. Organizational level data were sought from clinician expert representatives of specialist obesity services across Australia in 2017. Fifteen of 16 representatives of current services in New South Wales (n = 8), Queensland (n = 1), Victoria (n = 2), South Australia (n = 3), and the Australian Capital Territory (n = 1) provided data. The composition of services varied substantially between hospitals, and patient access to services and effective treatments were limited by strict entry criteria (e.g. body mass index 40 kg/m2 or higher with specific complication/s), prolonged wait times, geographical location (major cities only) and out-of-pocket costs. Of these services, 47% had a multidisciplinary team (MDT), 53% had an exercise physiologist/physiotherapist, 53% had a bariatric surgeon and 33% had pharmacotherapy resources. Key gaps included staffing components of the MDT (psychologist, exercise physiologist/physiotherapist) and access to publicly funded weight loss pharmacotherapy and bariatric surgery. There was consensus on the need for significant improvements in staff, physical infrastructure, access to services, education/training in obesity medicine and targeted research funding. Based on the small number of existing, often under-resourced specialist obesity services that are located only in a few major cities, the vast majority of Australians with clinically severe obesity cannot access the specialist evidence based treatments needed.
Asunto(s)
Accesibilidad a los Servicios de Salud , Servicios de Salud , Hospitales Públicos , Obesidad Mórbida/terapia , Especialización , Programas de Reducción de Peso , Adulto , Actitud del Personal de Salud , Australia , Cirugía Bariátrica , Índice de Masa Corporal , Mantenimiento del Peso Corporal , Ciudades , Consenso , Ejercicio Físico , Personal de Salud , Recursos en Salud , Humanos , Grupo de Atención al Paciente , Fisioterapeutas , Encuestas y Cuestionarios , Pérdida de PesoRESUMEN
People experiencing a severe mental illness (SMI), such as schizophrenia, schizoaffective disorder, bipolar affective disorder or depression with psychotic features, have a 20-year mortality gap compared to the general population. This 'scandal of premature mortality' is primarily driven by preventable cardiometabolic disease, and recent research suggests that the mortality gap is widening. Multidisciplinary mental health teams often include psychiatrists, clinical psychologists, specialist mental health nurses, social workers and occupational therapists, offering a range of pharmacological and nonpharmacological treatments to enhance the recovery of clients who have experienced, or are experiencing a SMI. Until recently, lifestyle and life skills interventions targeting the poor physical health experienced by people living with SMI have not been offered in most routine clinical settings. Furthermore, there are calls to include dietary intervention as mainstream in psychiatry to enhance mental health recovery. With the integration of dietitians being a relatively new approach, it is important to review and assess the literature to inform practice. This review assesses the dietary challenges experienced by people with a SMI and discusses potential strategies for improving mental and physical health.
Asunto(s)
Dieta , Estilo de Vida , Trastornos Mentales , Nutricionistas , Antipsicóticos/administración & dosificación , Antipsicóticos/efectos adversos , Interacciones Alimento-Droga , Humanos , Obesidad/dietoterapia , Obesidad/etiología , Ingesta Diaria RecomendadaAsunto(s)
Enfermedades Cardiovasculares , Dieta Saludable , Trastornos Mentales , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/prevención & control , Humanos , Trastornos Mentales/complicaciones , Trastornos Mentales/dietoterapia , Trastornos Mentales/mortalidad , Índice de Severidad de la EnfermedadRESUMEN
Foam sclerotherapy is a widely used method to treat varicose veins disease. It is easy to use and apply, affordable, and has high efficiency that depends on foam stability upon injection. Since sclerotherapy is usually applied in a medical doctor's office, one of the most employed methods to generate foam is based on the Tessari technique which uses pumping cycles of liquid and air in-and-out of a double syringe system. Finally, the produced foam exits through a small orifice (â¼2mm) at the output of a three-way valve. The present work shows results regarding the factors that may influence foam stability (liquid to air ratio, type of connector, syringe diameter, number of pumping cycles, etc.) of a commonly used sclerosing agent (polidocanol). Furthermore, an effort is made to evaluate the effect of adding different substances on the stability of polidocanol foams (0.5% w/w) by altering the surface tension or/and the bulk and interfacial rheological properties of the fluids. It is shown that adding small concentrations of nonionic surfactants can increase foam stability with just a very small variation of the mean bubbles size.
Asunto(s)
Polietilenglicoles/química , Soluciones Esclerosantes/química , Tensoactivos/química , Formas de Dosificación , Estabilidad de Medicamentos , Glicerol/química , Polidocanol , Polisacáridos Bacterianos/química , Polisorbatos/química , Reología , Escleroterapia , Propiedades de Superficie , Jeringas , ViscosidadRESUMEN
BACKGROUND: Triple therapy with pegylated interferon, ribavirin and a protease inhibitor has proven efficacy in hepatitis C infection and is currently the standard of care. Interferon-based therapies have been, rarely, associated with the development of Type 1 diabetes mellitus, but few cases have yet been reported in triple therapy for hepatitis C. CASE REPORT: We describe a case of autoimmune Type 1 diabetes developing in a 23-year-old woman after initiation of triple therapy for chronic hepatitis C virus infection. The patient had the IL-28B gene polymorphism rs12979860 CT genotype, which is associated not only with antiviral therapy response but also with diabetes risk after liver transplantation for hepatitis C. CONCLUSION: Further studies are required to determine which individual characteristics may identify patients who are at risk of developing Type 1 diabetes when treated with interferon-based regimens for hepatitis C infection.
Asunto(s)
Antivirales/efectos adversos , Enfermedades Autoinmunes/inducido químicamente , Diabetes Mellitus Tipo 1/inducido químicamente , Hepatitis C Crónica/tratamiento farmacológico , Inhibidores de Proteasas/efectos adversos , Adulto , Antivirales/uso terapéutico , Enfermedades Autoinmunes/genética , Enfermedades Autoinmunes/inmunología , Diabetes Mellitus Tipo 1/genética , Diabetes Mellitus Tipo 1/inmunología , Quimioterapia Combinada/efectos adversos , Femenino , Predisposición Genética a la Enfermedad , Humanos , Interferón-alfa/efectos adversos , Interferón-alfa/uso terapéutico , Interferones , Interleucinas/genética , Oligopéptidos/efectos adversos , Oligopéptidos/uso terapéutico , Polietilenglicoles/efectos adversos , Polietilenglicoles/uso terapéutico , Polimorfismo de Nucleótido Simple , Prolina/efectos adversos , Prolina/análogos & derivados , Prolina/uso terapéutico , Inhibidores de Proteasas/uso terapéutico , Ribavirina/efectos adversos , Ribavirina/uso terapéutico , Adulto JovenRESUMEN
BACKGROUND: People with severe mental illness have a 20-year life-expectancy shortfall. The majority of antipsychotic medications are associated with obesity and heightened diabetes risk. People with severe mental illness less frequently achieve benchmarked diabetes care, often attributed to poor adherence, lower clinical attendance and documented medical biases in treatment. This case is presented to highlight the profound effect medication change can have on diabetes control. CASE REPORT: A 56-year-old man with a 42-year history of schizophrenia had required clozapine treatment for the preceding 14 years. Type 2 diabetes and obesity occurred within 4 years of clozapine instigation. Glycaemic control had been continuously poor, despite frequent contact with diabetes services and multiple medications, including insulin at a dose exceeding 200 IU daily. Request for consideration of antipsychotic review and close interaction with the psychiatry team was initiated at the diabetes outpatient clinic. A gradual medication switch from clozapine to aripiprazole was associated with a reduction in HbA(1c) from 80 to 50 mmol/mol (9.5 to 6.7%) over 4 months, associated with a weight loss of 10 kg. Over the ensuing 2 years, the improvement in HbA(1c) has endured, with total weight loss of 13 kg and halving of insulin requirements. CONCLUSION: This case illustrates the benefits of engagement between endocrinologists and psychiatrists to achieve the shared goal of improved physical health in severe mental illness. Greater interdisciplinary collaboration will help bridge the life-expectancy gap in severe mental illness and may assist in preventing disabling diabetes complications in this vulnerable patient group.
Asunto(s)
Antipsicóticos/administración & dosificación , Clozapina/administración & dosificación , Diabetes Mellitus Tipo 2/inducido químicamente , Obesidad/inducido químicamente , Piperazinas/uso terapéutico , Quinolonas/uso terapéutico , Esquizofrenia/tratamiento farmacológico , Antipsicóticos/efectos adversos , Aripiprazol , Glucemia/metabolismo , Clozapina/efectos adversos , Esquema de Medicación , Hemoglobina Glucada/metabolismo , Humanos , Hipoglucemiantes/administración & dosificación , Insulina/administración & dosificación , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Pérdida de Peso/efectos de los fármacosRESUMEN
Achieving clinical and biochemical targets in type 2 diabetes mellitus (diabetes) is fundamental to preventing diabetic microvascular and macrovascular complications. These clinical imperatives are made more challenging in the setting of obesity. This review examines the evidence for bariatric surgery as a means of optimizing diabetes care, addressing diabetes resolution, glucose and lipid metabolism and cardiac effects. Mechanistic evidence of diabetes amelioration is summarized. The question of when bariatric surgery should be offered in the course of obesity-associated diabetes is discussed. Current guidelines and specialist society recommendations for bariatric surgery in diabetes are summarized.
Asunto(s)
Cirugía Bariátrica , Diabetes Mellitus Tipo 2/cirugía , Obesidad Mórbida/cirugía , Cirugía Bariátrica/efectos adversos , Cirugía Bariátrica/métodos , Índice de Masa Corporal , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/metabolismo , Medicina Basada en la Evidencia , Humanos , Obesidad Mórbida/complicaciones , Obesidad Mórbida/metabolismo , Guías de Práctica Clínica como Asunto , Factores de Riesgo , Pérdida de PesoAsunto(s)
Enfermedades Cardiovasculares/prevención & control , Diabetes Mellitus Tipo 2/prevención & control , Hipoglucemiantes/uso terapéutico , Metformina/uso terapéutico , Trastornos Psicóticos/complicaciones , Antipsicóticos/efectos adversos , Enfermedades Cardiovasculares/complicaciones , Humanos , Obesidad/prevención & control , Aumento de PesoRESUMEN
Bariatric surgery may be an effective treatment for obese heart failure patients, enabling access to cardiac transplantation and/or improvement of symptoms. We report the outcomes of two morbidly obese patients with end-stage heart failure, where obesity precluded cardiac transplantation and underwent laparoscopic gastric banding. A 42 year-old male with idiopathic dilated cardiomyopathy weighing 124.4 kg (BMI 42 kg/m(2)) lost 34 kg and was successfully transplanted 11 months later. A 40 year-old woman with familial dilated cardiomyopathy weighing 105 kg (BMI 40 kg/m(2)) lost 14 kg with sufficient symptomatic resolution to no longer require cardiac transplantation. In selected patients with severe heart failure and concomitant morbid obesity, bariatric surgery may be a reasonable treatment option.
Asunto(s)
Gastroplastia , Insuficiencia Cardíaca/cirugía , Obesidad Mórbida/cirugía , Adulto , Femenino , Insuficiencia Cardíaca/complicaciones , Trasplante de Corazón , Humanos , Masculino , Obesidad Mórbida/complicacionesRESUMEN
BACKGROUND: Obesity and type 2 diabetes mellitus are characterized by insulin resistance and 'low-grade inflammation'; however, the pathophysiological link is poorly understood. To determine the relative contribution of obesity and insulin resistance to systemic 'inflammation', this study comprehensively characterized circulating immune cells in different grades of obesity. METHODS: Immune cell phenotypes and activation status were analysed by flow cytometry cross-sectionally in morbidly obese (n = 16, body mass index (BMI) 42.2 ± 5.4 kg/m2), overweight (n = 13, BMI 27.4 ± 1.6 kg/m2) and normal weight (n = 12, BMI 22.5 ± 1.9 kg/m2) subjects. RESULTS: Obese, but not overweight subjects, had increased activation marker expression on neutrophils, monocytes, T-lymphocytes and polarization of T helper cells towards a pro-inflammatory type 1-phenotype (Th1). Th1 numbers correlated positively with the degree of insulin resistance (homeostasis model assessment, p < 0.05). Lymphocytes from obese subjects showed reduced insulin-stimulated AKT-phosphorylation in vitro. Supra-physiological insulin concentrations did not affect T-cell differentiation, which under normal circumstances would promote an anti-inflammatory T helper type 2-phenotype. CONCLUSIONS: These results show that morbid obesity is characterized by circulating immune cells that are activated and insulin resistant, with the T-cell balance polarized towards a pro-inflammatory Th1 phenotype. The loss of insulin-induced suppression of inflammatory phenotypes in circulating immune cells could contribute to the systemic and adipose tissue inflammation found in morbid obesity.
Asunto(s)
Biomarcadores/metabolismo , Diabetes Mellitus Tipo 2/etiología , Inflamación/inmunología , Resistencia a la Insulina , Células Secretoras de Insulina/inmunología , Obesidad Mórbida/complicaciones , Linfocitos T/inmunología , Tejido Adiposo/inmunología , Tejido Adiposo/metabolismo , Composición Corporal , Índice de Masa Corporal , Diabetes Mellitus Tipo 2/metabolismo , Femenino , Citometría de Flujo , Humanos , Inflamación/metabolismo , Insulina/metabolismo , Células Secretoras de Insulina/metabolismo , Masculino , Persona de Mediana Edad , Sobrepeso/inmunología , Sobrepeso/metabolismo , Linfocitos T/metabolismoRESUMEN
This study addresses the paucity of research on the prospective relationship between a range of inflammatory markers and symptoms of depression and anxiety during aging. In the Sydney Memory and Aging Study, the relationships between remitted depression, current and first onset of symptoms of depression or anxiety (Geriatric Depression Scale and Goldberg Anxiety Scale (GDS, GAS), and markers of systemic inflammation (C-reactive protein (CRP), interleukins-1ß, -6, -8, -10, -12, plasminogen activator inhibitor-1 (PAI-1), serum amyloid A, tumor necrosis factor-α, and vascular adhesion molecule-1) were investigated. The sample consists of N=1037 non-demented community-dwelling elderly participants aged 70-90 years assessed at baseline and after 2-years. All analyses were adjusted for gender, age, years of education, total number of medical disorders diagnosed by a doctor, cardiovascular disorders, endocrine disorders, smoking, body mass index, currently using anti-depressants, NSAIDS or statins and diabetes mellitus. The results show a significant linear relationship between increasing levels of IL-6 and depressive symptoms at baseline only, whereas IL-8 was associated with depressed symptoms at baseline and at 2 years follow-up. In addition, IL-8 was associated with first onset of mild to moderate depressive symptoms over 2 years. Logistic regression analyses showed that PAI-1 (OR=1.37, 95% CI=1.10-1.71, p=0.005) was associated with remitted depression. Results for anxiety symptoms were negative. The findings are suggestive of IL-6 and IL-8 being associated with current symptoms and IL-8 being associated with first onset of depressive symptoms, whereas PAI-1 could be regarded as a marker of remitted depression.
Asunto(s)
Envejecimiento/sangre , Ansiedad/sangre , Depresión/sangre , Memoria/fisiología , Anciano , Anciano de 80 o más Años , Envejecimiento/psicología , Biomarcadores/sangre , Proteína C-Reactiva/metabolismo , Femenino , Estudios de Seguimiento , Humanos , Inflamación/sangre , Interleucinas/sangre , Masculino , Pruebas Neuropsicológicas , Inhibidor 1 de Activador Plasminogénico/sangre , Valor Predictivo de las Pruebas , Escalas de Valoración Psiquiátrica , Factores de Riesgo , Factor de Necrosis Tumoral alfa/sangre , Molécula 1 de Adhesión Celular Vascular/sangreRESUMEN
CONTEXT: Obesity-related chronic inflammation is implicated in the pathogenesis of type 2 diabetes (T2D). OBJECTIVE: The objective of the study was to determine the effects of weight loss on immune cells in T2D and prediabetes. DESIGN AND SETTING: Thirteen obese subjects with T2D or prediabetes underwent 24 wk dietary energy restriction with gastric banding surgery at 12 wk. MAIN OUTCOME MEASURES: Measures included weight, waist, and insulin resistance; surface activation marker expression on circulating immune cells; T-helper cell polarization: type 1 (Th1), type 2 (Th2); adipose tissue macrophage number and activation in sc and visceral adipose tissue. RESULTS: Mean total weight loss was 13.5%. There were significant decreases in expression of proinflammatory activation markers: granulocyte CD11b, monocyte CD66b, and T cell CD69 and CD25. Proinflammatory Th1 cell numbers fell by greater than 80%, as did the Th1 to Th2 ratio. The fall in Th1 to Th2 ratio related to weight (P < 0.05) and waist loss (P < 0.05). Reduction in immune cell activation was more pronounced in subjects with prediabetes. Weight and abdominal fat loss were predicted by lower activation of adipose tissue macrophage in sc and visceral adipose tissue (P < 0.05). CONCLUSIONS: Energy restriction before and after gastric banding attenuates activation of circulating immune cells of the innate and adaptive immune system in T2D and prediabetes. The role of immune cells in the chronic inflammation of obesity and T2D requires further investigation.
Asunto(s)
Inmunidad Adaptativa/fisiología , Cirugía Bariátrica , Diabetes Mellitus Tipo 2/inmunología , Inmunidad Innata/fisiología , Estado Prediabético/inmunología , Pérdida de Peso/fisiología , Tejido Adiposo/metabolismo , Adulto , Anciano , Antropometría , Biomarcadores , Recuento de Células , Ingestión de Energía/fisiología , Femenino , Citometría de Flujo , Intolerancia a la Glucosa/metabolismo , Humanos , Inflamación/metabolismo , Macrófagos/inmunología , Masculino , Persona de Mediana Edad , Obesidad Mórbida/complicaciones , Obesidad Mórbida/inmunología , Linfocitos T Colaboradores-Inductores/inmunología , Células TH1/inmunología , Células Th2/inmunología , Adulto JovenRESUMEN
Patients infected with human immunodeficiency virus are living longer since the introduction of combination antiretroviral therapy more than a decade ago - but at what cost? Highly active antiretroviral therapy has been associated with lipodystrophy and associated metabolic derangements such as dyslipidaemia, insulin resistance and diabetes. These complications are likely to contribute to an increased risk of premature and accelerated atherosclerosis with growing concern about potential cardiovascular consequences.